# HR070803 in Combination With Oxaliplatin, S-1 Versus NALIRIFOX as Adjuvant Therapy for Pancreatic Cancer

> **NCT06383078** · PHASE2 · NOT_YET_RECRUITING · sponsor: **The First Affiliated Hospital with Nanjing Medical University** · enrollment: 120 (estimated)

## Conditions studied

- Efficacy and Safety

## Interventions

- **DRUG:** HR070803
- **DRUG:** Oxaliplatin
- **DRUG:** Tegafur
- **DRUG:** Folinic acid
- **DRUG:** 5-Fluorouracil

## Key facts

- **NCT ID:** NCT06383078
- **Lead sponsor:** The First Affiliated Hospital with Nanjing Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-04-20
- **Primary completion:** 2027-03-01
- **Final completion:** 2027-12-30
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2024-04-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06383078

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06383078, "HR070803 in Combination With Oxaliplatin, S-1 Versus NALIRIFOX as Adjuvant Therapy for Pancreatic Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06383078. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*